These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 21458064)

  • 21. Bifunctional conjugates comprising β-cyclodextrin, polyethylenimine, and 5-fluoro-2'- deoxyuridine for drug delivery and gene transfer.
    Lu X; Ping Y; Xu FJ; Li ZH; Wang QQ; Chen JH; Yang WT; Tang GP
    Bioconjug Chem; 2010 Oct; 21(10):1855-63. PubMed ID: 20853891
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Combination efficacy of doxorubicin and adenoviral methioninase gene therapy with prodrug selenomethionine.
    Gupta A; Miki K; Xu M; Yamamoto N; Moossa AR; Hoffman RM
    Anticancer Res; 2003; 23(2B):1181-8. PubMed ID: 12820369
    [TBL] [Abstract][Full Text] [Related]  

  • 23. DNA/chitosan nanocomplex as a novel drug carrier for doxorubicin.
    Cheng X; Zhang F; Zhou G; Gao S; Dong L; Jiang W; Ding Z; Chen J; Zhang J
    Drug Deliv; 2009 Apr; 16(3):135-44. PubMed ID: 19514973
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Suicide gene therapy of human breast cancer in SCID mice model by the regulation of Tet-On.
    Hu WX; Zeng ZJ; Luo SQ; Chen Q
    Chin Med J (Engl); 2004 Mar; 117(3):434-9. PubMed ID: 15043787
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Endosomal pH-activatable poly(ethylene oxide)-graft-doxorubicin prodrugs: synthesis, drug release, and biodistribution in tumor-bearing mice.
    Zhou L; Cheng R; Tao H; Ma S; Guo W; Meng F; Liu H; Liu Z; Zhong Z
    Biomacromolecules; 2011 May; 12(5):1460-7. PubMed ID: 21332185
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Altered expression of proliferation-inducing and proliferation-inhibiting genes might contribute to acquired doxorubicin resistance in breast cancer cells.
    Saleh EM; El-Awady RA; Abdel Alim MA; Abdel Wahab AH
    Cell Biochem Biophys; 2009; 55(2):95-105. PubMed ID: 19593673
    [TBL] [Abstract][Full Text] [Related]  

  • 27. CPI-0004Na, a new extracellularly tumor-activated prodrug of doxorubicin: in vivo toxicity, activity, and tissue distribution confirm tumor cell selectivity.
    Dubois V; Dasnois L; Lebtahi K; Collot F; Heylen N; Havaux N; Fernandez AM; Lobl TJ; Oliyai C; Nieder M; Shochat D; Yarranton GT; Trouet A
    Cancer Res; 2002 Apr; 62(8):2327-31. PubMed ID: 11956091
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Prostate cancer cell death produced by the co-delivery of Bcl-xL shRNA and doxorubicin using an aptamer-conjugated polyplex.
    Kim E; Jung Y; Choi H; Yang J; Suh JS; Huh YM; Kim K; Haam S
    Biomaterials; 2010 Jun; 31(16):4592-9. PubMed ID: 20206379
    [TBL] [Abstract][Full Text] [Related]  

  • 29. In vivo treatment of tumors using host-guest conjugated nanoparticles functionalized with doxorubicin and therapeutic gene pTRAIL.
    Fan H; Hu QD; Xu FJ; Liang WQ; Tang GP; Yang WT
    Biomaterials; 2012 Feb; 33(5):1428-36. PubMed ID: 22079004
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Co-delivery of PDTC and doxorubicin by multifunctional micellar nanoparticles to achieve active targeted drug delivery and overcome multidrug resistance.
    Fan L; Li F; Zhang H; Wang Y; Cheng C; Li X; Gu CH; Yang Q; Wu H; Zhang S
    Biomaterials; 2010 Jul; 31(21):5634-42. PubMed ID: 20430433
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Synergistic gene and drug tumor therapy using a chimeric peptide.
    Han K; Chen S; Chen WH; Lei Q; Liu Y; Zhuo RX; Zhang XZ
    Biomaterials; 2013 Jun; 34(19):4680-9. PubMed ID: 23537665
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Polymer conjugates of the highly potent cytostatic drug 2-pyrrolinodoxorubicin.
    Studenovsky M; Ulbrich K; Ibrahimova M; Rihova B
    Eur J Pharm Sci; 2011 Jan; 42(1-2):156-63. PubMed ID: 21075206
    [TBL] [Abstract][Full Text] [Related]  

  • 33. CD10 is a key enzyme involved in the activation of tumor-activated peptide prodrug CPI-0004Na and novel analogues: implications for the design of novel peptide prodrugs for the therapy of CD10+ tumors.
    Pan C; Cardarelli PM; Nieder MH; Pickford LB; Gangwar S; King DJ; Yarranton GT; Buckman D; Roscoe W; Zhou F; Salles A; Chen TH; Horgan K; Wang YH; Nguyen T; Bebbington CR
    Cancer Res; 2003 Sep; 63(17):5526-31. PubMed ID: 14500390
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A P-glycoprotein- and MRP1-independent doxorubicin-resistant variant of the MCF-7 breast cancer cell line with defects in caspase-6, -7, -8, -9 and -10 activation pathways.
    Park SJ; Wu CH; Safa AR
    Anticancer Res; 2004; 24(1):123-31. PubMed ID: 15015586
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Plasmin-activated doxorubicin prodrugs containing a spacer reduce tumor growth and angiogenesis without systemic toxicity.
    Devy L; de Groot FM; Blacher S; Hajitou A; Beusker PH; Scheeren HW; Foidart JM; Noël A
    FASEB J; 2004 Mar; 18(3):565-7. PubMed ID: 14734647
    [TBL] [Abstract][Full Text] [Related]  

  • 36. REIC/Dkk-3 overexpression downregulates P-glycoprotein in multidrug-resistant MCF7/ADR cells and induces apoptosis in breast cancer.
    Kawasaki K; Watanabe M; Sakaguchi M; Ogasawara Y; Ochiai K; Nasu Y; Doihara H; Kashiwakura Y; Huh NH; Kumon H; Date H
    Cancer Gene Ther; 2009 Jan; 16(1):65-72. PubMed ID: 18654608
    [TBL] [Abstract][Full Text] [Related]  

  • 37. STX140 is efficacious in vitro and in vivo in taxane-resistant breast carcinoma cells.
    Newman SP; Foster PA; Stengel C; Day JM; Ho YT; Judde JG; Lassalle M; Prevost G; Leese MP; Potter BV; Reed MJ; Purohit A
    Clin Cancer Res; 2008 Jan; 14(2):597-606. PubMed ID: 18223236
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Nano-assemblies of J-aggregates based on a NIR dye as a multifunctional drug carrier for combination cancer therapy.
    Song X; Zhang R; Liang C; Chen Q; Gong H; Liu Z
    Biomaterials; 2015 Jul; 57():84-92. PubMed ID: 25913253
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Vascular targeting of doxorubicin using cationic liposomes.
    Wu J; Lee A; Lu Y; Lee RJ
    Int J Pharm; 2007 Jun; 337(1-2):329-35. PubMed ID: 17275230
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Folate-mediated poly(3-hydroxybutyrate-co-3-hydroxyoctanoate) nanoparticles for targeting drug delivery.
    Zhang C; Zhao L; Dong Y; Zhang X; Lin J; Chen Z
    Eur J Pharm Biopharm; 2010 Sep; 76(1):10-6. PubMed ID: 20472060
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.